深部脑磁刺激对帕金森病模型大鼠运动症状治疗的安全性评价

发布时间：2018-02-25 20:29

本文关键词： 帕金森病深部脑磁刺激运动行为学不良反应安全性　出处：《首都医科大学学报》2017年02期 　论文类型：期刊论文

【摘要】：目的评估深部脑磁刺激(deep-brain magnetic stimulation,DMS)对单侧帕金森病(Parkinson's disease,PD)模型大鼠运动障碍的治疗作用及DMS治疗的安全性。方法立体定位注射六羟基多巴胺(6-hydroxydopamine,6-OHDA)于大鼠右侧纹状体制备单侧帕金森病模型,假手术对照组(Sham组)依据同样方法注射0.9%(质量分数)氯化钠注射液。利用阿扑吗啡筛选模型后,造模成功的动物采用均衡随机化分组的方式分为模型对照组(Model组)、δ节律DMS治疗组(DMS-δ组)、γ节律DMS治疗组(DMS-γ组),其中两种DMS治疗组行每天40 min、持续4周的DMS治疗。通过碰壁实验检测大鼠运动行为,通过大鼠体质量的测定、外周血淋巴细胞的分类及计数、主要组织器官的苏木精-伊红(Hematoxylin-Eosin staining,HE)染色评价DMS治疗的安全性。结果 (1)检测大鼠运动行为显示,DMS-γ治疗组损伤侧的肢体利用率显著高于Model组,差异具有统计学意义(P0.05),而DMS-δ组相较于Model组差异无统计学意义(P0.05)。(2)Sham组、Model组、DMS-δ组、DMS-γ组大鼠体质量差异均无统计学意义(P0.05)。(3)Sham组、Model组、DMS-δ组、DMS-γ组大鼠外周血总淋巴细胞与T细胞的数量和比例差异均无统计学意义(P0.05)。DMS-δ组大鼠的自然杀伤(natural killer,NK)细胞数量和比例相较于Model组有显著改善。(4)HE染色显示,DMS对大鼠主要器官包括心、肝、脾、肺、肾、胃、小肠、睾丸均未造成明显的组织病理变化。结论 DMS-γ治疗可改善PD大鼠双侧肢体不对称性运动障碍,且DMS对PD大鼠运动行为的治疗中无明显不良反应,表明DMS在对PD大鼠运动症状的治疗中具有很好的安全性。
[Abstract]:Objective to evaluate the therapeutic effect of deep-brain magnetic stimulation (magnetic) on motor disorders in rats with unilateral Parkinson's disease (PD) and the safety of DMS treatment. Methods A stereotactic injection of 6-hydroxydopamine 6-hydroxydopamine 6-OHDAin was made in the right striatum of rats. Lateral Parkinson's disease model, Sham-operated control group (Sham group) was injected with 0.9 sodium chloride injection (mass fraction) according to the same method. The model was screened with apomorphine. The successful animals were randomly divided into three groups: model group (model group), DMS group (未 rhythm), DMS- 纬 group (纬 rhythm DMS). Two DMS treatment groups were treated with DMS for 40 min per day for 4 weeks. The movement behavior of rats was detected by the experiment of bumping through the wall. By measuring the body mass of rats, the peripheral blood lymphocytes were classified and counted. The safety of DMS was evaluated by hematoxylin-eosin hematoxylin-eosin staining in main tissues and organs. Results 1) the limb utilization rate of injured side in DMS- 纬 treatment group was significantly higher than that in Model group. There was no significant difference between DMS- 未 group and Model group. There was no significant difference in body mass between DMS- 未 group and DMS- 未 group compared with Model group. There was no significant difference in body mass between DMS- 未 group and DMS- 纬 group. There was no significant difference in body mass between DMS- 未 group and DMS- 未 group compared with DMS- 未 group, DMS- 未 group, DMS- 纬 group, DMS- 未 group, DMS- 未 group, DMS- 纬 group, DMS- 未 group, DMS- 未 group, DMS- 未 group, DMS- 未 group and DMS- 纬 group. The number and proportion of natural killer killer NKK cells in DMS- 未 group were significantly improved compared with that in Model group. The results showed that the number and proportion of natural killer NK cells in DMS- 未 group were significantly better than those in Model group, which showed that the number and proportion of natural killer NK cells in DMS- 未 group were significantly better than those in Model group. Liver, spleen, lung, kidney, stomach, small intestine and testis did not cause obvious histopathological changes. Conclusion DMS- 纬 therapy can improve bilateral limb asymmetric motor disorder in PD rats, and there is no obvious adverse reaction in the treatment of PD rats with DMS. The results suggest that DMS is safe in the treatment of motor symptoms in PD rats.
【作者单位】：首都医科大学基础医学院神经生物学系;教育部神经变性病重点实验室;北京脑重大疾病研究院;首都医科大学基础医学院生理学与病理生理学系;
【基金】：国家重点基础研究发展计划(“973”计划)(2011CB504100) 北京市自然科学基金项目(7082008) 北京市科学技术委员会专项资助(Z161100002616007) 北京市属高等学校创新团队建设与教师职业发展计划项目(IDHT20140514)~~
【分类号】：R742.5;R-332

【相似文献】